Screening Cancer Readiness Through Education and Empowerment for Newcomer Women (SCREEN)
The Effect of Online Education on Knowledge and Attitudes Toward Cancer Screening Among Migrant Women: A Randomized Controlled Trial
Purpose: This study was conducted to determine the effect of an online educational intervention on migrant women's knowledge and attitudes toward cancer screening.
DesigN:This study was designed as a two-arm, parallel-group, randomized controlled trial with pre-test and post-test assessments.
Method: The study population will consist of women registered at the Cancer Early Diagnosis, Screening and Training Center (KETEM) affiliated with the Erzincan Provincial Health Directorate. The sample size was calculated based on a two-group (intervention and control) and two-measurement (pre-test and post-test) study design. Using repeated-measures ANOVA with a medium effect size (d = 0.25), a significance level of 5% (α = 0.05), and a statistical power of 80% (1 - β = 0.80), the required sample size was determined to be 34 participants per group (34 in the intervention group and 34 in the control group), resulting in a minimum total sample of 68 participants. To account for potential attrition, it was planned to recruit 80 participants (approximately 20% more than the minimum required sample size).
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Ezgi Demirtürk Selçuk, PhD
- Telefoonnummer: +905448502161
- E-mail: demirturkezgi@gmail.com
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
Women aged 30-70 years. Able to read and write. Able to speak and understand Turkish. Have access to the internet at home or in the workplace. Own a smartphone or have access to a smartphone belonging to a family member that can be used by the participant.
Have no hearing, visual, cognitive, or orthopedic impairments that would prevent participation in the study.
-
Exclusion Criteria:Presence of cognitive, visual, or orthopedic impairment that may interfere with participation in the study.
Diagnosis of a psychiatric disorder.
-
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: controlegroep
|
Women assigned to the control group who are registered at the Cancer Early Diagnosis, Screening and Training Center (KETEM) will be contacted and invited to participate in the study.
During the initial meeting, written informed consent will be obtained, after which the Personal Information Form and study questionnaires will be administered to collect baseline (pre-test) data.
An appointment for the follow-up assessment will be scheduled approximately four weeks later.
Five weeks after the baseline assessment, participants will be contacted by telephone to complete the post-test assessment.
No educational intervention will be provided to the control group during the study period.
After completion of the post-test assessment, participants in the control group will be offered the same cancer screening education program in accordance with the ethical principle of equity.
|
|
Experimenteel: SCREEN
|
Women assigned to the intervention group will be contacted by telephone using the contact information registered at the Cancer Early Diagnosis, Screening and Training Center (KETEM).
For participants without a registered telephone number, home visits will be conducted using the addresses recorded in the KETEM database.
Following completion of the baseline (pre-test) assessment, participants in the intervention group will receive an online cancer screening education program developed in accordance with the Turkish National Cancer Control Program of the General Directorate of Public Health, Ministry of Health of the Republic of Türkiye.
The educational intervention will be delivered in three online sessions via WhatsApp video calls.
During each session, participants will have the opportunity to ask questions, which will be answered by the researcher.
Prior to each session, reminder text messages will be sent to participants' mobile phones to notify them of the date and time of the schede
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Cancer Screening Knowledge Scale
Tijdsspanne: From baseline to 5 weeks after baseline
|
The Cancer Screening Knowledge Scale is a 25-item questionnaire designed to assess participants' knowledge regarding cancer screening.
Total scores range from 0 to 25, with higher scores indicating greater knowledge.
|
From baseline to 5 weeks after baseline
|
|
Cancer Screening Attitude Scale-Short Form
Tijdsspanne: From baseline to 5 weeks after baseline
|
The Cancer Screening Attitude Scale-Short Form is a 15-item questionnaire used to assess participants' attitudes toward cancer screening.
Total scores range from 15 to 75, with higher scores indicating more positive attitudes toward cancer screening.
|
From baseline to 5 weeks after baseline
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 0413
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .